(F2) Granulocyte colony-stimulating factor (G-CSF) in the treatment of myelodysplastic syndromes (MDS)
Cited by 0
Related Papers
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
|The Journal of Experimental Medicine|1991|623
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
|Blood|2007|332
Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model
|British Journal of Haematology|1997|314
Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice
|Bone Marrow Transplantation|2013|310
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297